17.59
price up icon1.79%   0.31
after-market Handel nachbörslich: 17.20 -0.39 -2.22%
loading
Schlusskurs vom Vortag:
$17.28
Offen:
$16.86
24-Stunden-Volumen:
340.63K
Relative Volume:
2.55
Marktkapitalisierung:
$658.22M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
-6.8178
EPS:
-2.58
Netto-Cashflow:
$-18.50M
1W Leistung:
-0.40%
1M Leistung:
-1.90%
6M Leistung:
+21.81%
1J Leistung:
+17.34%
1-Tages-Spanne:
Value
$16.86
$18.00
1-Wochen-Bereich:
Value
$16.86
$18.96
52-Wochen-Spanne:
Value
$11.35
$21.79

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name
Firmenname
Entrada Therapeutics Inc
Name
Telefon
857-305-1825
Name
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Name
Mitarbeiter
177
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-12
Name
Neueste SEC-Einreichungen
Name
TRDA's Discussions on Twitter

Vergleichen Sie TRDA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TRDA
Entrada Therapeutics Inc
17.59 658.22M 239.40M 104.44M -18.50M 2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-06 Eingeleitet ROTH MKM Buy
2024-01-05 Eingeleitet Oppenheimer Outperform
2023-04-03 Eingeleitet H.C. Wainwright Buy

Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten

pulisher
Dec 18, 2024

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com

Dec 18, 2024
pulisher
Dec 17, 2024

(TRDA) Proactive Strategies - Stock Traders Daily

Dec 17, 2024
pulisher
Dec 16, 2024

Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN

Dec 16, 2024
pulisher
Dec 13, 2024

XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Dec 13, 2024
pulisher
Dec 10, 2024

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St

Dec 09, 2024
pulisher
Dec 08, 2024

Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World

Dec 08, 2024
pulisher
Dec 07, 2024

Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance

Dec 07, 2024
pulisher
Dec 07, 2024

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Dec 07, 2024
pulisher
Dec 03, 2024

Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus.com

Dec 03, 2024
pulisher
Dec 03, 2024

Entrada Therapeutics CFO sells shares worth nearly $120,000 By Investing.com - Investing.com Nigeria

Dec 03, 2024
pulisher
Dec 03, 2024

Entrada Therapeutics president sells $320,619 in stock By Investing.com - Investing.com Nigeria

Dec 03, 2024
pulisher
Dec 03, 2024

Entrada Therapeutics CFO sells shares worth nearly $120,000 - Investing.com India

Dec 03, 2024
pulisher
Dec 03, 2024

Entrada Therapeutics president sells $320,619 in stock - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

Entrada Therapeutics stock hits 52-week high at $20.5 By Investing.com - Investing.com Canada

Dec 03, 2024
pulisher
Nov 28, 2024

Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 28, 2024
pulisher
Nov 26, 2024

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - MSN

Nov 26, 2024
pulisher
Nov 26, 2024

(TRDA) Investment Analysis and Advice - Stock Traders Daily

Nov 26, 2024
pulisher
Nov 26, 2024

Connor Clark & Lunn Investment Management Ltd. Has $2.22 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 26, 2024
pulisher
Nov 17, 2024

Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com

Nov 15, 2024
pulisher
Nov 13, 2024

500: Something went wrong - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 11, 2024

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 11, 2024
pulisher
Nov 10, 2024

HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World

Nov 10, 2024
pulisher
Nov 08, 2024

HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia

Nov 07, 2024
pulisher
Nov 07, 2024

Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics : Corporate Presentation - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 05, 2024
pulisher
Nov 02, 2024

Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN

Nov 02, 2024
pulisher
Oct 28, 2024

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World

Oct 28, 2024
pulisher
Oct 19, 2024

Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 18, 2024

Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat

Oct 18, 2024

Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Entrada Therapeutics Inc-Aktie (TRDA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
MPM BIOVENTURES 2018, L.P.
10% Owner
Dec 11 '24
Sale
20.23
21,787
440,751
4,381,062
MPM BioVentures 2014, L.P.
10% Owner
Dec 10 '24
Sale
20.77
22,935
476,360
4,402,849
MPM BioVentures 2014, L.P.
10% Owner
Dec 11 '24
Sale
20.23
21,787
440,751
4,381,062
WENTWORTH KORY JAMES
Chief Financial Officer
Dec 02 '24
Option Exercise
2.10
5,000
10,500
78,849
WENTWORTH KORY JAMES
Chief Financial Officer
Nov 29 '24
Option Exercise
2.10
1,000
2,100
74,849
WENTWORTH KORY JAMES
Chief Financial Officer
Dec 02 '24
Sale
20.00
5,000
99,978
73,849
WENTWORTH KORY JAMES
Chief Financial Officer
Nov 29 '24
Sale
19.97
1,000
19,970
73,849
Sethuraman Natarajan
President, Research & Develop.
Dec 03 '24
Sale
20.15
11,703
235,786
144,997
Sethuraman Natarajan
President, Research & Develop.
Dec 02 '24
Sale
20.26
4,088
82,834
156,700
Sethuraman Natarajan
President, Research & Develop.
Nov 29 '24
Sale
20.00
100
2,000
160,788
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Kapitalisierung:     |  Volumen (24h):